Zenosense Inc. (ZENO) On the Heels of Early Cancer Detection Device Breakthrough
Any person diagnosed with cancer or any medical practitioner intimate with the study of this disease has learned that one of the most critical pieces of data for determining prognosis is the stage the cancer is in when first discovered. The more advanced the cancer stage at diagnosis, the lower the survival rate. The earlier the stage when discovered, the greater the chances of survival. To simply state, ‘the earlier the better,’ could easily be called as the understatement of the century. Our inquiring minds beg for answers to logical questions preceded with, ‘If only…’ or ‘What if there were a way…’
Zenosense Inc. (OTCQB: ZENO) is a company that not only asks, ‘What if,’ they are a company that devotes its time, attention and resources on producing an answer. Specifically, ZENO is committed to developing a non-invasive, cost-effective early detection screening method for detecting lung cancer. Long term, shareholder value intentions are believed to offer noticeable improvements in survival and mortality rates.
The company operates on the cutting edge of executing on the challenge of developing practical, cost-effective medical devices that will detect at the earliest of stages, deadly lung cancer bacteria and other cancers in a patient’s exhaled breath. And as would be expected, the promising news coming from company development efforts is generating positive activity and excitement.
In November of 2014, ZENO announced plans to manufacture a pre-market prototype device that would be evaluated during a lung cancer detection trial in a clinical setting. Zenon Biosystem, Zenosense’s development partner, assumed a leadership position in a project that would be responsible for manufacturing the prototype. In preparation for the planned trial and to meet the standards of the trial’s protocol design, Zenon planned to manufacture two pre-commercial devices of identical design to ensure that trial results could be duplicated. A month later, Zenon announced that it would be collaborating with a university and a large university hospital in Madrid, Spain on a nine month long lung cancer detection trial that will facilitate clinical tests on breath samples from 400 people.
Zenosense feels that a cost-effective, breath-analyzing lung cancer detector that is proven to meet or exceed the accuracy of low-dose Computed Tomography (CT) scanning will have broad appeal and demand. As a result, company development efforts have welcomed the news that a team of university research scientists and their hospital have recognized the potential for the technology. A positive outcome from the planned lung cancer detection trial will be a significant step toward a major healthcare breakthrough and quite possibly provide a much needed answer to the question, ‘What if…’
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Any person diagnosed with cancer or any medical practitioner intimate with the study of this disease has learned that one of the most critical pieces of data for determining prognosis is the stage the cancer is in when first discovered. The more advanced the cancer stage at diagnosis, the lower the survival rate. The earlier the stage when discovered, the greater the chances of survival. To simply state, ‘the earlier the better,’ could easily be called as the understatement of the century. Our inquiring minds beg for answers to logical questions preceded with, ‘If only…’ or ‘What if there were a way…’
Zenosense Inc. (OTCQB: ZENO) is a company that not only asks, ‘What if,’ they are a company that devotes its time, attention and resources on producing an answer. Specifically, ZENO is committed to developing a non-invasive, cost-effective early detection screening method for detecting lung cancer. Long term, shareholder value intentions are believed to offer noticeable improvements in survival and mortality rates.
The company operates on the cutting edge of executing on the challenge of developing practical, cost-effective medical devices that will detect at the earliest of stages, deadly lung cancer bacteria and other cancers in a patient’s exhaled breath. And as would be expected, the promising news coming from company development efforts is generating positive activity and excitement.
In November of 2014, ZENO announced plans to manufacture a pre-market prototype device that would be evaluated during a lung cancer detection trial in a clinical setting. Zenon Biosystem, Zenosense’s development partner, assumed a leadership position in a project that would be responsible for manufacturing the prototype. In preparation for the planned trial and to meet the standards of the trial’s protocol design, Zenon planned to manufacture two pre-commercial devices of identical design to ensure that trial results could be duplicated. A month later, Zenon announced that it would be collaborating with a university and a large university hospital in Madrid, Spain on a nine month long lung cancer detection trial that will facilitate clinical tests on breath samples from 400 people.
Zenosense feels that a cost-effective, breath-analyzing lung cancer detector that is proven to meet or exceed the accuracy of low-dose Computed Tomography (CT) scanning will have broad appeal and demand. As a result, company development efforts have welcomed the news that a team of university research scientists and their hospital have recognized the potential for the technology. A positive outcome from the planned lung cancer detection trial will be a significant step toward a major healthcare breakthrough and quite possibly provide a much needed answer to the question, ‘What if…’
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
